alexa Universally Protective Vaccines: A Revolution In Modern Vaccinology
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Geert Vanden Bossche
University Leuven, Belgium
Univac NV, Belgium
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
To eliminate safety risks related to infectivity, inactivated pathogens and more suitably, well-characterized pathogen-derived antigens (Ags) have increasingly been used as immunogens in modern vaccines. The selection of these Ags is usually based on their capacity to induce immune responses that correlate with natural protection. These Ags, however, are known to be antigenically variable or conformation-dependent (e.g., B cell epitopes) and/or subject to immunogenetic restriction (e.g., linear, T-cell epitopes). In addition, the immunogenicity of good vaccinal Ags is largely dependent on memory CD4+ T helper cells. However, activation of the latter upon natural infection or foreign Ag exposure of genetically predisposed subjects can occasionally lead to immune pathology. Priming of CD4+ T helper cells by adjuvanted vaccines is, therefore, increasingly raising safety concerns. On the other hand, Ags that are highly conserved and vulnerable because of their exposure on the surface of infected or pathologically altered host cells are either not immunogenic or subvert the host immune system. Hence, they are not used as vaccinal Ags in contemporary vaccines. We consider that new technologies enabling immune targeting of these Ags by natural, MHC allotype-independent immune effector memory cells is the new Holy Grail in modern vaccinology.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version